• Genta Inc., of Berkeley Heights, N.J., reported results from its Phase IIb confirmatory trial of tesetaxel in 41 patients with advanced gastric cancer who progressed on at least one prior chemotherapy regimen that included a platinum compound (cisplatin, oxaliplati or carboplatin) and a fluoropyrimidine compound (5-fluorouracil or capecitabine [Xeloda, Hoffman-La Roche]).